A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy
Latest Information Update: 06 May 2022
Price :
$35 *
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 01 Feb 2014 Results published in the Drugs and Aging.
- 20 May 2009 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
- 22 Oct 2005 New trial record.